First-line nivolumab plus ipilimumab for unresectable MPM in China: a cost-effectiveness analysis

BACKGROUND: The regimen of nivolumab plus ipilimumab (NI) has been recommended by the National Comprehensive Cancer Network Clinical Practice Guidelines in Oncology-Malignant Pleural Mesothelioma (Version 1.2022) and Chinese Guidelines for the Clinical Diagnosis and Treatment of Malignant Pleural Me...

Descripción completa

Detalles Bibliográficos
Autores principales: Yang, Liu, Song, Xiaobing, Zeng, Wanxian, Zheng, Zhiwei, Lin, Wenqiang
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2023
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10580582/
https://www.ncbi.nlm.nih.gov/pubmed/37845696
http://dx.doi.org/10.1186/s13023-023-02925-w

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10580582/
https://www.ncbi.nlm.nih.gov/pubmed/37845696
http://dx.doi.org/10.1186/s13023-023-02925-w

Ejemplares similares